Holen Sie sich die Stockscreener-App
19.02
9.06%
1.58
Schlusskurs vom Vortag:
$17.44
Offen:
$17.59
24-Stunden-Volumen:
116.95K
Relative Volume:
0.65
Marktkapitalisierung:
$839.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.64%
1M Leistung:
+31.26%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.59
$19.24
1-Wochen-Bereich:
$16.46
$20.19
52-Wochen-Spanne:
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Firmenname
Sionna Therapeutics Inc
Sektor
Branche
Telefon
617-819-2020
Adresse
21 HICKORY DRIVE, SUITE 500, WALTHAM
Vergleichen Sie SION mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
19.02 | 817.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Eingeleitet | Guggenheim | Buy |
| 2025-03-04 | Eingeleitet | Stifel | Buy |
| 2025-03-04 | Eingeleitet | TD Cowen | Buy |
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
Is Sionna Therapeutics Inc. a good long term investmentExplosive market performance - Autocar Professional
What analysts say about Sionna Therapeutics Inc. stockDynamic investment growth - jammulinksnews.com
What drives Sionna Therapeutics Inc. stock priceOutperformance with explosive growth - jammulinksnews.com
Sionna Therapeutics Inc. Stock Analysis and ForecastHigh-yield investments - printweek.in
What makes Sionna Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Sionna Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser
How Sionna Therapeutics Inc. stock performs during market volatilityFree Membership Group - Newser
Sionna Therapeutics (NASDAQ:SION) Shares Gap Up on Insider Buying Activity - Defense World
Major Investment Alert: Sionna Therapeutics Gains a Boost from TPG GP A, LLC - TipRanks
Sionna Therapeutics, Inc.(NasdaqGM: SION) added to Russell Microcap Growth Index - MarketScreener
Sionna Therapeutics, Inc.(NasdaqGM: SION) added to S&P Global BMI Index - MarketScreener
Sling Therapeutics, Inc. Appoints Ken Lock as Chief Commercial Officer - MarketScreener
Sionna Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Sionna Therapeutics Holds Annual Stockholders Meeting - TipRanks
Sionna Therapeutics reports annual meeting results - Investing.com
Sionna's experimental CFTR modulators show promise in preclinical tests - Cystic Fibrosis News Today
Odyssey Therapeutics pulls plug on IPO plans - The Business Journals
Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months - BioSpace
Odyssey pulls back from IPO plans as public markets remain frozen - Endpoints News
Sionna Therapeutics advances CF treatment with new data By Investing.com - Investing.com South Africa
Sionna Therapeutics advances CF treatment with new data - Investing.com India
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewswire
Sionna Therapeutics: A Potential Game-Changer in Cystic Fibrosis Treatment - AInvest
NBD1 stabilizers safe in healthy volunteers, Sionna says - Cystic Fibrosis News Today
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
2 Soaring Stocks Wth More Upside Potential - AOL.com
Transcript : Sionna Therapeutics, Inc.Special Call - marketscreener.com
Sionna advances cystic fibrosis treatments to new trials By Investing.com - Investing.com South Africa
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Benzinga
Stifel analysts reiterate buy rating on Sionna Therapeutics stock By Investing.com - Investing.com Canada
Sionna Therapeutics Announces Positive Phase 1 Results For SION-719, SION-451 In Cystic Fibrosis - Nasdaq
Sionna advances cystic fibrosis treatments to new trials - Investing.com Australia
Sionna Therapeutics Reports Positive Phase 1 Trial Results - TipRanks
Finanzdaten der Sionna Therapeutics Inc-Aktie (SION)
Es liegen keine Finanzdaten für Sionna Therapeutics Inc (SION) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):